REDWOOD CITY, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Maxygen, Inc. will host a conference call to discuss the company’s third quarter 2007 financial results at 11:30 a.m. ET (8:30 a.m. PT) on Thursday, November 1, 2007. Russell Howard, Maxygen’s chief executive officer, will host the call. A press release announcing Maxygen’s third quarter 2007 financial results will be issued earlier that same day at approximately 9:00 a.m. ET (6:00 a.m. PT).
Participants in the U.S. can access the call by dialing 800.561.2718 and using the passcode 15245655. International participants can dial 617.614.3525 and use the same passcode. A live webcast of the conference call will be available on the Maxygen web site at http://www.maxygen.com/webcasts.
Telephone and webcast replays of the conference call will be available for approximately 30 days. To access the telephone replay, dial 888.286.8010 (U.S.) or 617.801.6888 (international) and use the passcode 76932136. To access the webcast archive, go to http://www.maxygen.com/webcasts.
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Our lead program, MAXY-G34, is an improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in our pipeline is a novel Factor VIIa for the treatment of hemophilia. Maxygen’s approach to drug discovery and development may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market. http://www.maxygen.com
CONTACT: Michele Boudreau of Maxygen, Inc., +1-650-279-2088,
michele.boudreau@maxygen.com
Web site: http://www.maxygen.com/
